Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in the life sciences sector. The company was incorporated in 2021 and is based in Oakland, California.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
3/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13D/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
SC 13G - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
8-K/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
D - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
25-NSE - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)
425 - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
8-K - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Filer)
425 - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
8-K - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Filer)
424B3 - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Filer)
425 - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ("CERo") today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combination, the combined public company was renamed "CERo Therapeutics Holdings, Inc." The shares of common stock of the combined public company have been approved for listing on the Nasdaq Global Market and are expected to commence trading under the ticker symbol "CERO" t
CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical trials in 2024. Anticipated cash resources will fund the advancement of CERo's lead product candidate, CER-1236 to early clinical data in hematological oncology The transaction reflects a pre-money equity value of $50 million for CERo, pro forma equity capitalization of $145 million and is expected to provide up to $13.7 million held in trust, assuming no redemptions by current Phoenix stockholders and no additional capital raised Business combination expected to be completed
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company sponsored by Phoenix Biotech Sponsor, LLC and formed for the purpose of acquiring or merging with one or more businesses, today announced the mutual termination of their previously announced business combination agreement due to current market conditions. "Intrinsic was encouraged by the positive feedback from prospective investors regarding the attractiveness of our novel and capital-efficient appro
Intrinsic's pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform the treatment of Gut-Brain Axis and inflammatory disorders through multiple mechanisms of action, including modulation of the gut microbiome and immune systemAnticipated cash resources will fund a Phase 2b clinical trial of Intrinsic's lead, HMO-based drug candidate, OM002 (2'-fucosyllactose, or 2'FL), in over 400 patients with the constipation dominant form of irritable bowel syndrome (IBS-C)—estimated to affect ~5.0 million patients in the United States alone—and advance Intrinsic's pipeline of
Shares of Big Lots, Inc. (NYSE:BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ:MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ:BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated vide
Shares of Compass Minerals International, Inc. (NYSE:CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 million. Compass Minerals International shares fell 9% to $20.52 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Syra Health Corp. (NASDAQ:SYRA) shares jumped 310% to $4.71 after the company announced a partnership for a federal contract valued at $75 billion. Hitek Global Inc. (NASDAQ:HKIT) surged 305% to $4.622
RNA biotech TransCode Therapeutics Inc (NASDAQ:RNAZ) withdrew its S-1 filing with the SEC that it made in late November. TransCode said that the withdrawal reflects TransCode's belief that "current market conditions are not conducive for an offering on terms that would be in the best interests of the company's stockholders." The lead candidate, dubbed TTX-MC138, is currently in the preclinical stage and is designed to treat metastatic cancers by inhibiting "microRNA-10b" to eliminate the metastasis. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers, including breast, pancreatic, ovarian, colon, and glioblastomas. Also see: TransCode Therapeutics
Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company sponsored by Phoenix Biotech Sponsor, LLC and formed for the purpose of acquiring or merging with one or more businesses, today announced the mutual termination of their previously announced business combination agreement due to current market conditions. "Intrinsic was encouraged by the positive feedback from prospective investors regarding the attractiveness of our novel and capital-efficient approach to developing transformative new therape
Intrinsic's pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform the treatment of Gut-Brain Axis and inflammatory disorders through multiple mechanisms of action, including modulation of the gut microbiome and immune system Anticipated cash resources will fund a Phase 2b clinical trial of Intrinsic's lead, HMO-based drug candidate, OM002 (2'-fucosyllactose, or 2'FL), in over 400 patients with the constipation dominant form of irritable bowel syndrome (IBS-C)—estimated to affect ~5.0 million patients in the United States alone—and advance Intrinsic's